Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In glioblastoma metastasis, the malignant mGSC cells express markers of mesenchymal GSC subtype (MES-GSC), such as CD44 and YK-40 and their major obstacle seems to be propagating in the in various organs' microenvironments, different from the niches that home GSCs in the primary glioblastoma.
|
31654711 |
2020 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also found that elevated serum/plasma YKL-40 had significant prognostic effects on OS in various cancer subgroups such as gastrointestinal tumors (HR, 1.37; 95% CI 1.18-1.58), ovarian cancer (HR, 2.27; 95% CI 1.69-3.06), melanoma (HR, 1.77; 95% CI 1.18-2.67), lung cancer (HR, 1.73; 95% CI 1.35-2.23), urologic neoplasms (HR, 1.61; 95% CI 1.08-2.40) and glioblastoma (HR, 1.23; 95% CI 1.07-1.42); in contrast, the prognostic effect of serum/plasma YKL-40 was not statistically significant in breast cancer (HR, 1.07; 95% CI 0.98-1.17).
|
31624472 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma.
|
31561550 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, this study identifies candidate changes in secreted proteins from NF1 deficient glioma cells that could influence the tumor microenvironment, and suggests a direct link between NF1 loss and increased tumor cell production of CHI3L1 and endoglin, two factors implicated in mesenchymal identity in glioblastoma.
|
29643433 |
2018 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab.
|
29467925 |
2018 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma.
|
29729901 |
2018 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence.
|
28430288 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM.
|
26212701 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beyond known key players for GBM such as ERBB2, PMS2, or CHI3L1, we identified over 50 genes that have not been associated to GBM so far.
|
25537509 |
2015 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue.
|
25629266 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future.
|
24842123 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient.
|
22495652 |
2012 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored.
|
21953450 |
2011 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis.
|
21385870 |
2011 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
|
20174854 |
2010 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resveratrol represses YKL-40 expression in human glioma U87 cells.
|
21029458 |
2010 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intracranial injection of purified CD133+, not CD133- GBM daughter cells, can lead to the development of YKL-40+ infiltrating tumors that display hypervascularity and pseudopalisading necrosis-like features in mouse brain.
|
19468690 |
2009 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
|
19255724 |
2009 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization.
|
15867231 |
2005 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells.
|
15771622 |
2005 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Neither SAGE nor Northern analysis revealed the presence of HC gp-39 mRNA in the glioblastoma cell line, thus the detection of increased quantities of this mRNA in GBMs may be associated with activated macrophages.
|
12957359 |
2003 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 serum levels were substantially elevated in many of the GBM patients.
|
12154041 |
2002 |